Drug Trial Radar · NCT07833735
A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of SYS6043 ± Bevacizumab ± Chemotherapy in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Oct 15, 2026
Primary completion
Oct 15, 2028
Study completion Oct 15, 2029
Sponsor
- Lead sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, safety run-in, dose-expansion and cohort-expansion Phase I/II study designed to evaluate the safety, tolerability, PK profile and preliminary anti-tumor efficacy of SYS6043 (a B7-H3-targeted ADC) in participants with advanced/metastatic solid tumors. The trial consists of two phases: the Phase I component is the safety run-in study, and the Phase II component includes the dose-expansion study and cohort-expansion study.
Conditions
- Advanced Solid Tumors
Interventions
SYS6043Drug
Participants in the experimental group will receive SYS6043, Q3W administered on Day 1 of each cycle..
bevacizumabDrug
Participants in the experimental group will receive bevacizumab Q3W administered on Day 1 of each cycle.
carboplatinDrug
Participants in the experimental group will receive carboplatin Q3W administered on Day 1 of each cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicities (DLTs) -(Phase I: Safety Run-in Study)Time frame: 21 days for Arm 1-3.
- Incidence of adverse events (AEs) and serious adverse events (SAEs) assessed by CTCAE 6.0-(Phase I: Safety Run-in Study)Time frame: 2 years
- Maximum tolerated dose (MTD) (if any) ) of SYS6043 with or without bevacizumab with or without carboplatin-(Phase I: Safety Run-in Study)Time frame: Up to 1year
- Recommended phase 2 dose (RP2D) of SYS6043 with or without bevacizumab with or without carboplatin-(Phase I: Safety Run-in Study)Time frame: 2 years
- Incidence of adverse events (AEs) and serious adverse events (SAEs) assessed by CTCAE 6.0-(Phase II: Dose-expansion Study)Time frame: Up to 1year
- PFS rate assessed by RECIST Version 1.1(Phase II: Cohort-expansion Study)Time frame: 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.